|Bid||201.40 x 800|
|Ask||201.46 x 1300|
|Day's Range||198.68 - 201.77|
|52 Week Range||117.06 - 201.77|
|Beta (5Y Monthly)||0.37|
|PE Ratio (TTM)||32.93|
|Earnings Date||Jan 29, 2021|
|Forward Dividend & Yield||3.40 (1.71%)|
|Ex-Dividend Date||Feb 11, 2021|
|1y Target Est||189.29|
The company has said it will provide detailed data on the treatment on March 13. The stock is up some 19% over the past week.
The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.
Shares of Eli Lilly & Co. gained 0.8% in premarket trading on Wednesday, the day after the drugmaker announced a deal worth up to $1.6 billion with Merus to develop three antibody therapies aimed at treating cancer. The Dutch company's stock was down 5.1% in premarket trading on Wednesday. The deal, which includes research and a licensing agreement, is designed to give Merus an upfront payment of $40 million, a $20 million equity investment, and up to $540 million in potential milestone payments. Over the last year, Lilly's stock has gained 42.2%, shares of Merus are up 45.5%, and the S&P 500 has rallied 14.5%.